For the segment, Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI, discussed the Company’s recently announced 6-week interim biomarker data from its ongoing Phase 2a study in ...

Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a repair response. The Independent Data Monitoring Commi ...

A 19-year-old woman with a history of depression and anxiety symptoms was admitted to the hospital because of seizure, ...

Identifying early predictors of chronic kidney disease (CKD) progression in patients with lupus nephritis may help define a high-risk group.

In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of ...

Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

As Merck & Co. rolls out a widespread cost-cutting initiative, the pharma is dropping an autoimmune asset acquired a few years ago in a nearly $2 billion biotech takeover.

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.